Roberta Di Blasi

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun et al. · Blood Advances · 2020 · 387 citations · Full text

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi et al. · Nature Medicine · 2022 · 343 citations · Full text

Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with <scp>non‐Hodgkin</scp> lymphoma treated with B‐cell depleting immunotherapy

Rémy Duléry, Sylvain Lamure, Marc Delord et al. · American Journal of Hematology · 2021 · 156 citations · Full text

Bloodstream infections caused by <i>Klebsiella pneumoniae</i> in onco‐hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey

Enrico Maria Trecarichi, Livio Pagano, Bruno Martino et al. · American Journal of Hematology · 2016 · 145 citations · Full text

Klebsiella Pneumoniae, Antibiotic Resistance, Clinical Impact +16

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy et al. · Blood · 2022 · 131 citations · Full text

Aggressive B-cell Lymphoma, Immunology, Pathology +18